261 related articles for article (PubMed ID: 30204261)
21. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway.
Nader E; Grau M; Fort R; Collins B; Cannas G; Gauthier A; Walpurgis K; Martin C; Bloch W; Poutrel S; Hot A; Renoux C; Thevis M; Joly P; Romana M; Guillot N; Connes P
Nitric Oxide; 2018 Dec; 81():28-35. PubMed ID: 30342855
[TBL] [Abstract][Full Text] [Related]
22. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
23. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
Exp Biol Med (Maywood); 2008 Dec; 233(12):1510-7. PubMed ID: 18849548
[TBL] [Abstract][Full Text] [Related]
24. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
[TBL] [Abstract][Full Text] [Related]
25. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo.
Ballas SK; Dover GJ; Charache S
Am J Hematol; 1989 Oct; 32(2):104-11. PubMed ID: 2757007
[TBL] [Abstract][Full Text] [Related]
26. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
27. Growth Hormone/Insulin-like Growth Factor 1 Axis Associated with Modifier Factors in Children with Sickle Cell Anemia.
Costa-Júnior DAD; Santos APP; da Silva CM; Velloso-Rodrigues C
Endocr Metab Immune Disord Drug Targets; 2022; 22(9):954-962. PubMed ID: 35240969
[TBL] [Abstract][Full Text] [Related]
28. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
Lemonne N; Möckesch B; Charlot K; Garnier Y; Waltz X; Lamarre Y; Antoine-Jonville S; Etienne-Julan M; Hardy-Dessources MD; Romana M; Connes P
Clin Hemorheol Microcirc; 2017; 67(2):141-148. PubMed ID: 28759962
[TBL] [Abstract][Full Text] [Related]
29. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
Huang Z; Louderback JG; King SB; Ballas SK; Kim-Shapiro DB
Am J Hematol; 2001 Jul; 67(3):151-6. PubMed ID: 11391710
[TBL] [Abstract][Full Text] [Related]
30. HbF-promoting polymorphisms may specifically reduce the residual risk of cerebral vasculopathy in SCA children with alpha-thalassemia.
Joly P; Bonello-Palot N; Badens C; Pissard S; Chamouine A; Bernaudin F; Bertrand Y; Connes P; Renoux C
Clin Hemorheol Microcirc; 2021; 77(3):267-272. PubMed ID: 33216016
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
[TBL] [Abstract][Full Text] [Related]
32. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
Sheehan VA; Crosby JR; Sabo A; Mortier NA; Howard TA; Muzny DM; Dugan-Perez S; Aygun B; Nottage KA; Boerwinkle E; Gibbs RA; Ware RE; Flanagan JM
PLoS One; 2014; 9(10):e110740. PubMed ID: 25360671
[TBL] [Abstract][Full Text] [Related]
33. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
36. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
37. Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.
Ender KL; Lee MT; Sheth S; Licursi M; Crotty J; Barral S; Green NS
J Pediatr Hematol Oncol; 2011 Oct; 33(7):496-9. PubMed ID: 21941141
[TBL] [Abstract][Full Text] [Related]
38. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
Conran N; Fattori A; Saad ST; Costa FF
Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
[TBL] [Abstract][Full Text] [Related]
39. Fetal hemoglobin and alpha thalassemia modulate the phenotypic expression of HbSD-Punjab.
Patel DK; Purohit P; Dehury S; Das P; Dutta A; Meher S; Patel S; Bag S; Mashon RS; Das K
Int J Lab Hematol; 2014 Aug; 36(4):444-50. PubMed ID: 24245819
[TBL] [Abstract][Full Text] [Related]
40. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Koshy M; Dorn L; Bressler L; Molokie R; Lavelle D; Talischy N; Hoffman R; van Overveld W; DeSimone J
Blood; 2000 Oct; 96(7):2379-84. PubMed ID: 11001887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
